Allergic Rhino-Conjunctivitis – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2012', provides an overview of the Allergic Rhino-Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Allergic Rhino-Conjunctivitis Therapeutic Products under Development, Key Players in Allergic Rhino-Conjunctivitis Therapeutics, Allergic Rhino-Conjunctivitis Pipeline Overview, Allergic Rhino-Conjunctivitis Pipeline, Allergic Rhino-Conjunctivitis Pipeline Assessment
Summary
Global Markets Direct’s, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2012', provides an overview of the Allergic Rhino-Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis.
- A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Allergic Rhino-Conjunctivitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Allergic Rhino-Conjunctivitis Therapeutic Products under Development, Key Players in Allergic Rhino-Conjunctivitis Therapeutics, Allergic Rhino-Conjunctivitis Pipeline Overview, Allergic Rhino-Conjunctivitis Pipeline, Allergic Rhino-Conjunctivitis Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Allergic Rhino-Conjunctivitis Overview
Therapeutics Development
An Overview of Pipeline Products for Allergic Rhino-Conjunctivitis
Allergic Rhino-Conjunctivitis Therapeutics under Development by Companies
Allergic Rhino-Conjunctivitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Allergic Rhino-Conjunctivitis Therapeutics – Products under Development by Companies
Allergic Rhino-Conjunctivitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Allergic Rhino-Conjunctivitis Therapeutics Development
Merck & Co., Inc.
ALK-Abello A/S
Stallergenes S.A.
Cytos Biotechnology AG
Allergopharma Joachim Ganzer KG
Laboratorios LETI S.L.
Allergic Rhino-Conjunctivitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CYT003-QbG10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-7243 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olea Europaea Pollen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Modified Allergen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0704rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mutaflor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Ragweed Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0206st - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Depigoid Birch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gpASIT + TM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Birch Pollen Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0701rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osiris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phleum pratense - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergic Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
Allergic Rhino-Conjunctivitis Therapeutics - Dormant Products
Allergic Rhino-Conjunctivitis – Product Development Milestones
Featured News & Press Releases
Mar 21, 2012: Paladin Labs Receives Canadian Approval For Oralair
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
May 24, 2011: Paladin Labs Files New Drug Submission For Oralair
Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Allergic Rhino-Conjunctivitis, H1 2012
Products under Development for Allergic Rhino-Conjunctivitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Merck & Co., Inc., H1 2012
ALK-Abello A/S, H1 2012
Stallergenes S.A., H1 2012
Cytos Biotechnology AG, H1 2012
Allergopharma Joachim Ganzer KG, H1 2012
Laboratorios LETI S.L., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Allergic Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
Allergic Rhino-Conjunctivitis Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Allergic Rhino-Conjunctivitis, H1 2012
Products under Development for Allergic Rhino-Conjunctivitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Global Markets Direct Report Coverage
Allergic Rhino-Conjunctivitis Overview
Therapeutics Development
An Overview of Pipeline Products for Allergic Rhino-Conjunctivitis
Allergic Rhino-Conjunctivitis Therapeutics under Development by Companies
Allergic Rhino-Conjunctivitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Allergic Rhino-Conjunctivitis Therapeutics – Products under Development by Companies
Allergic Rhino-Conjunctivitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Allergic Rhino-Conjunctivitis Therapeutics Development
Merck & Co., Inc.
ALK-Abello A/S
Stallergenes S.A.
Cytos Biotechnology AG
Allergopharma Joachim Ganzer KG
Laboratorios LETI S.L.
Allergic Rhino-Conjunctivitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CYT003-QbG10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-7243 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olea Europaea Pollen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Modified Allergen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0704rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mutaflor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Ragweed Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0206st - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Depigoid Birch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gpASIT + TM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Birch Pollen Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0701rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osiris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phleum pratense - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergic Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
Allergic Rhino-Conjunctivitis Therapeutics - Dormant Products
Allergic Rhino-Conjunctivitis – Product Development Milestones
Featured News & Press Releases
Mar 21, 2012: Paladin Labs Receives Canadian Approval For Oralair
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
May 24, 2011: Paladin Labs Files New Drug Submission For Oralair
Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Allergic Rhino-Conjunctivitis, H1 2012
Products under Development for Allergic Rhino-Conjunctivitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Merck & Co., Inc., H1 2012
ALK-Abello A/S, H1 2012
Stallergenes S.A., H1 2012
Cytos Biotechnology AG, H1 2012
Allergopharma Joachim Ganzer KG, H1 2012
Laboratorios LETI S.L., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Allergic Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
Allergic Rhino-Conjunctivitis Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Allergic Rhino-Conjunctivitis, H1 2012
Products under Development for Allergic Rhino-Conjunctivitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
